H1 strength masks Q2 seasonal weakness; margins below guidance
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
H1 delivery strong; Q2 miss on revenue and margins. Prior 35-40% FY27 growth now unclear if achievable; new 30%+ CAGR is multi-year, not specific.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
H1 growth of 78% YoY (₹534 Cr) and strong order book underscore demand recovery. However, Q2 revenue collapsed 41% YoY (₹177 Cr) and NPM at 1.5% falls far short of 2.5-3% guidance, signalling execution and margin challenges. Management's shift to long-term 30%+ CAGR (vs prior 35-40% FY27) hints at cautious reset. Key risk: sequential deterioration suggests H2 momentum may be weaker than the bullish tone suggests.
₹177.1 Cr
Revenue · −41.2% YoY₹2.7 Cr
Reported PAT · +5.7% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
H1 delivered strong 78% YoY revenue growth (₹534 Cr vs ₹300 Cr)
METH1 FY27 ₹534 Cr standalone, H1 FY26 ₹300 Cr; Q2 FY27 ₹177.1 Cr down 41% YoY; Q1 FY27 ≈ ₹357 Cr implied
Order book looks very encouraging; 70-80% capacity utilization in H2
PartialQ2 was lean/seasonal; management attributes Q2 weakness to seasonality not demand; H2 demand claim not yet evidenced
EBITDA margins 9-10% range maintained
METQ2 OPM 11.2% (within range if comparable to EBITDA); H1 EBITDA growth 60% YoY aligns with margin stability claim
NPM striving towards 3%, with improvement from lower interest costs
OVERSTATEDQ2 NPM 1.5%, well below 2.5-3% prior guidance; Q2 attributable to seasonality and interest; PAT grew only 5.7% YoY despite much higher capacity
Capacity expansions on track; EMS operational in 45 days, AC indoor 70% done by December
METManagement confirmed timelines; no contradictory evidence in delivered result; expansion plan credible
Earnings quality
What changed since the last call
Growth guidance reset
DowngradePrior FY27 target 35-40% growth; now 30%+ CAGR (longer-term, less specific). Implies FY27 growth may fall short of 35%.
NPM trajectory delayed
DowngradePrior target 2.5-3% NPM; Q2 delivered 1.5%, deferred improvement to future quarters vs expected near-term.
Capacity expansion scope confirmed
NeutralEMS, AC, compressor expansions proceeding on track; no scope reduction or acceleration vs prior call.
Customer additions in AC
UpgradeAdded 3 new Tier 1/2 customers in AC in addition to anchor customer; was not detailed prior.
The Q&A
Analysts pressed on compressor unit economics (unit cost ₹1,400-1,500 vs smaller players), margin trajectory, and debt refinancing. Management was direct on most points (70% utilization, 40-60% outsourcing mix maintained) but deflected on: (a) specific customer names, (b) Nasik Phase 2 revenue, (c) exact NPM improvement timeline. Overall tone was confident but slightly defensive on margin questions.
Outsourcing mix — Shreyansh Jain, Unknown
Answered40-60% outsourcing mix maintained as company guideline. Industry trending towards outsourcing; we benefit by capping ourselves.
Compressor advantage — Piyush Jain, Unknown
AnsweredWe are only OEM/ODM supplying compressors; competing with imports on cost. Margins lower than AC/EMS now; expect improvement as backward integration (assembly) and imports reduce.
Debt management — Kunal Tokas, Unknown
AnsweredPlan to refinance ₹150 Cr OCD (bridge capital) to bank debt. Target debt-equity <1. Bank borrowing at 8.25-8.4% cost.
AC capacity utilization — Kunal Tokas, Unknown
PartialOrder book ramp-up + new customer additions. Hands full now; no capacity for new customers until expanded.
Nasik Phase 2 revenue — Hemant Soni, Unknown
DodgedComponent (Sanand/Chennai) is <5% of revenue. Refrain from giving specific estimate; will grow 30-35% over 5-year block.
EMS facility utilization — Hemant Soni, Unknown
AnsweredDesigned for captive first, external sales to follow. 70% of added capacity for captive; expandable for external.
CapEx completion timeline — Shreya Bajaj, Unknown
AnsweredNo further CapEx needed for peak revenue. Current ₹80-100 Cr FY27 CapEx sufficient; most tied up or spent. Balance of work matter of execution.
Inventory management — Shreyansh Jain, Unknown
AnsweredYes, mostly. Built for seasonal RAC demand (Oct onwards); will normalize as season progresses.
Freezer demand softness — Rajas Joshi, Unknown
PartialDemand strong; Q2 lean seasonally. Order book strong for Q3-Q4. Pass-through to brands ongoing; price stable last 6 months; pass-through slow but progressing.
AC capacity utilization — Rishabh Agrawal, Unknown
AnsweredCurrent 1M. IDU expansion to 15 lakh capacity; 70% enhancement done, 15 lakh/1.5M/1.6M capacity peak target; Q1 FY28 with 10 lakh base.
Guidance
FY27: 30%+ revenue CAGR (long-term), from ₹825 Cr base prior
MediumFramed as multi-year CAGR, not FY27-specific. H1 at 78% growth suggests FY27 will exceed 30% if H2 remains strong; but Q2 weakness suggests H2 may disappoint.
EBITDA margins 9-10% range; maintain consistency
HighQ2 OPM 11.2% within range; H1 EBITDA 56 Cr with 77% growth supports margin stability claim.
NPM: striving closer to 3% (vs 2.5-3% prior); deferred improvement
LowQ2 NPM 1.5%, well below target. Mgmt defers improvement to future quarters due to seasonality, interest costs, and working capital not yet optimized.
FY27 total CapEx ₹80-100 Cr (₹20-25 Cr product CapEx in refrigeration)
HighNo further CapEx needed; current plan sufficient to reach peak capacity. Most already spent or committed.
Risks the call surfaced
Execution risk
HighEMS (45 days), AC indoor (70% done, Dec target), compressor (end FY27 target), deep freezer expansion all in flight. Delays would undermine growth guidance.
Seasonality / demand risk
HighQ2 revenue -41% YoY (₹177 Cr vs ~₹301 Cr prior year). Attributed to seasonality, but magnitude steep. If H2 demand is softer than order book suggests, FY27 growth target misses.
Margin pressure
HighQ2 NPM 1.5% vs 2.5-3% guidance. Mgmt attributes to seasonality and interest; improvement deferred. If interest cost remains high or working capital doesn't improve, NPM stays depressed.
Competitive / pricing risk
MediumCompressors are new, competing with imported Chinese units. Mgmt expects margins to improve via backward integration (assembly) and as imports reduce. But timing and magnitude uncertain.
Customer concentration
MediumAnchor customer accounts for 40-50% of AC revenue. Loss or reduced offtake would significantly impact segment.
Management
Score 6/10. Mostly clear on numbers (H1 78% growth, EBITDA 9-10% guidance, debt ₹400 Cr). Deflected on specific customer names, Nasik Phase 2 revenue, and exact NPM timeline. Candid on challenges (Q2 lean, compressor margins, interest cost drag). H1 FY27 delivered 78% YoY growth (₹534 Cr) vs ₹300 Cr prior, hitting prior growth claims. Capacity expansions tracking schedule. But Q2 revenue miss (-41% YoY) and PAT growth only 5.7% YoY suggest execution is uneven (strong Q1, weak Q2).
1 · Q3-Q4 FY27
Seasonal demand upturn; order book monetization expected
2 · Dec 2026
AC indoor unit capacity expansion (targeting) + EMS facility live
3 · Q4 FY27 / Q1 FY28
Compressor capacity expansion to 6M units; backward integration in IDU/ODU begins
Key risk: sequential deterioration suggests H2 momentum may be weaker than the bullish tone suggests.
Informational and educational content only. Not investment advice.